Showing 49 to 60 of 75 results
Personalized mRNA Vaccines Show Promise in Pancreatic Cancer Treatment
A phase 1 clinical trial shows personalized mRNA vaccines generated a durable T-cell response in 50% of 16 patients with operable pancreatic cancer, lasting nearly eight years post-surgery, offering a potential new treatment for this deadly disease.
Personalized mRNA Vaccines Show Promise in Pancreatic Cancer Treatment
A phase 1 clinical trial shows personalized mRNA vaccines generated a durable T-cell response in 50% of 16 patients with operable pancreatic cancer, lasting nearly eight years post-surgery, offering a potential new treatment for this deadly disease.
Progress
44% Bias Score
Childhood Cancer Survival Rates in the Netherlands Significantly Increase
New data from the Netherlands Cancer Registry shows that the five-year survival rate for children diagnosed with cancer between 2010 and 2018 was 84 percent, compared to 74 percent for those diagnosed between 1990 and 1999; improvements in diagnosis and targeted treatments are responsible for this i...
Childhood Cancer Survival Rates in the Netherlands Significantly Increase
New data from the Netherlands Cancer Registry shows that the five-year survival rate for children diagnosed with cancer between 2010 and 2018 was 84 percent, compared to 74 percent for those diagnosed between 1990 and 1999; improvements in diagnosis and targeted treatments are responsible for this i...
Progress
32% Bias Score
Israel's Cancer Crisis: 33,570 Diagnoses and the Impact of National Crises
In 2024, approximately 33,570 Israelis were diagnosed with cancer, resulting in 12,000 deaths; the most common cancers varied by gender, with lung cancer showing a strong link to smoking; disruptions caused by the pandemic and Operation Iron Swords worsened outcomes; Israel's advanced cancer care of...
Israel's Cancer Crisis: 33,570 Diagnoses and the Impact of National Crises
In 2024, approximately 33,570 Israelis were diagnosed with cancer, resulting in 12,000 deaths; the most common cancers varied by gender, with lung cancer showing a strong link to smoking; disruptions caused by the pandemic and Operation Iron Swords worsened outcomes; Israel's advanced cancer care of...
Progress
36% Bias Score
Italy's Cancer Prevention Gap: Lifestyle Risks and Healthcare Shortcomings
In Italy, 6 million adults are obese, increasing their cancer risk, yet only 43% receive weight-loss advice from doctors; this highlights insufficient preventative care, particularly among economically disadvantaged individuals, necessitating a multi-pronged approach improving lifestyle intervention...
Italy's Cancer Prevention Gap: Lifestyle Risks and Healthcare Shortcomings
In Italy, 6 million adults are obese, increasing their cancer risk, yet only 43% receive weight-loss advice from doctors; this highlights insufficient preventative care, particularly among economically disadvantaged individuals, necessitating a multi-pronged approach improving lifestyle intervention...
Progress
40% Bias Score
Record High Cancer Survivor Rate in US, but Cardiovascular Risks Rise
The number of cancer survivors in the US exceeds 18 million, a record high due to early detection and effective treatments; however, these treatments can cause cardiovascular issues, leading to increased referrals to cardio-oncology clinics.
Record High Cancer Survivor Rate in US, but Cardiovascular Risks Rise
The number of cancer survivors in the US exceeds 18 million, a record high due to early detection and effective treatments; however, these treatments can cause cardiovascular issues, leading to increased referrals to cardio-oncology clinics.
Progress
28% Bias Score
Russia to Launch Personalized mRNA Cancer Vaccine in September 2025
Russia will introduce a personalized mRNA cancer vaccine for melanoma and some leukemia patients in September 2025, developed by the Gamaleya Research Institute with funding from President Putin; initial trials show promise.
Russia to Launch Personalized mRNA Cancer Vaccine in September 2025
Russia will introduce a personalized mRNA cancer vaccine for melanoma and some leukemia patients in September 2025, developed by the Gamaleya Research Institute with funding from President Putin; initial trials show promise.
Progress
64% Bias Score
Inavolisib Improves Outcomes in Pik3ca-Mutated Breast Cancer
A clinical trial (Inavo120) demonstrated that inavolisib, combined with palbociclib and fulvestrant, significantly improved progression-free and overall survival in 325 patients with hormone receptor-positive, HER2-negative, Pik3ca-mutated breast cancer compared to the standard therapy; the FDA appr...
Inavolisib Improves Outcomes in Pik3ca-Mutated Breast Cancer
A clinical trial (Inavo120) demonstrated that inavolisib, combined with palbociclib and fulvestrant, significantly improved progression-free and overall survival in 325 patients with hormone receptor-positive, HER2-negative, Pik3ca-mutated breast cancer compared to the standard therapy; the FDA appr...
Progress
40% Bias Score
Cancer Treatment Advancements Allow Fertility Preservation, But Raise New Challenges
Maggie Loucks, diagnosed with HER2-positive breast cancer at 28, chose a less aggressive chemotherapy regimen to preserve fertility, highlighting advancements in cancer treatment that prioritize quality of life alongside cancer survival, but also facing subsequent fertility challenges.
Cancer Treatment Advancements Allow Fertility Preservation, But Raise New Challenges
Maggie Loucks, diagnosed with HER2-positive breast cancer at 28, chose a less aggressive chemotherapy regimen to preserve fertility, highlighting advancements in cancer treatment that prioritize quality of life alongside cancer survival, but also facing subsequent fertility challenges.
Progress
40% Bias Score
Eleven Blockbuster Drugs to Transform Medicine by 2030
Clarivate's 2025 Drugs to Watch report identifies eleven innovative medicines projected to become blockbusters by 2030, significantly impacting various therapeutic areas, with diabetes/obesity and atopic dermatitis treatments anticipated to lead in revenue generation.
Eleven Blockbuster Drugs to Transform Medicine by 2030
Clarivate's 2025 Drugs to Watch report identifies eleven innovative medicines projected to become blockbusters by 2030, significantly impacting various therapeutic areas, with diabetes/obesity and atopic dermatitis treatments anticipated to lead in revenue generation.
Progress
36% Bias Score
Hamburg Cancer Registry Data Shows Stable Incidence, Lower Mortality
The Hamburg Cancer Registry reports that the average age of cancer diagnosis is 70, with less than 1% of cancer deaths occurring before age 50; in 2022, 11,232 new cases were reported in Hamburg, with breast, thyroid, and colorectal cancers being the most common among those under 50.
Hamburg Cancer Registry Data Shows Stable Incidence, Lower Mortality
The Hamburg Cancer Registry reports that the average age of cancer diagnosis is 70, with less than 1% of cancer deaths occurring before age 50; in 2022, 11,232 new cases were reported in Hamburg, with breast, thyroid, and colorectal cancers being the most common among those under 50.
Progress
20% Bias Score
mRNA Cancer Vaccines: Promising Trials, but No Approvals Yet
Despite initial hopes after the success of mRNA COVID-19 vaccines, no mRNA cancer vaccines have received approval yet; however, several are in clinical trials, showing potential for personalized cancer treatments but facing significant hurdles.
mRNA Cancer Vaccines: Promising Trials, but No Approvals Yet
Despite initial hopes after the success of mRNA COVID-19 vaccines, no mRNA cancer vaccines have received approval yet; however, several are in clinical trials, showing potential for personalized cancer treatments but facing significant hurdles.
Progress
32% Bias Score
Breakwater Study Shows Improved Outcomes for Colorectal Cancer Patients with BRAFV600 Mutations
A new study shows that a combined therapy of chemotherapy, encorafenib, and cetuximab significantly improves outcomes for colorectal cancer patients with BRAFV600 mutations, achieving a 68.7% response rate lasting over six months compared to 34.1% with standard chemotherapy.
Breakwater Study Shows Improved Outcomes for Colorectal Cancer Patients with BRAFV600 Mutations
A new study shows that a combined therapy of chemotherapy, encorafenib, and cetuximab significantly improves outcomes for colorectal cancer patients with BRAFV600 mutations, achieving a 68.7% response rate lasting over six months compared to 34.1% with standard chemotherapy.
Progress
40% Bias Score
Showing 49 to 60 of 75 results